Natural Product (NP) Details
| General Information of the NP (ID: NP8128) | |||||
|---|---|---|---|---|---|
| Name |
Rhein
|
||||
| Synonyms |
Rhein; 478-43-3; Monorhein; Rheic acid; Rhubarb Yellow; Cassic acid; 4,5-Dihydroxyanthraquinone-2-carboxylic acid; 4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; Chrysazin-3-carboxylic acid; 1,8-Dihydroxy-3-carboxyanthraquinone; Rheinic acid; NSC 38629; 1,8-Dihydroxyanthraquinone-3-carboxylic acid; MFCD00009618; 2-Anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; UNII-YM64C2P6UX; 4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; Rhein (1,8-dihydroxy-3-carboxyl anthraquinone); 9,10-Dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid; YM64C2P6UX; MLS000069639; CHEBI:8825; 2-Anthroic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; 4,5-Dihydroxy-2-anthraquinonecarboxylic acid; 4,5-DiOH-anthraquinone-2-COOH; SMR000058210; ST057726; dipropionyl rhein; 1,8-DIHYDROXY-3-CARBOXYL ANTHRAQUINONE; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthroic acid; Rhein(Monorhein); CCRIS 5129; C15H8O6; EINECS 207-521-4; BRN 2222155; Rhein - Monorhein; RHN; Rhein,(S); Rhein; Rhubarb Yellow; Rhein, technical grade; 4ie7; ACMC-209kan; regid855879; Rhein-[13C6]; DSSTox_CID_6000; Rhein, analytical standard; 1,8-dihydroxy-3-carboxyl-9,10-anthraquinone; DSSTox_RID_77984; DSSTox_GSID_26000; SCHEMBL25253; US9238626, Rhein; 4-10-00-04088 (Beilstein Handbook Reference); cid_10168; MLS006011744; CHEMBL418068; MEGxp0_001866; 4,5-dihydroxy-9,10-dioxo-anthracene-2-carboxylic acid; DTXSID4026000; ACon1_000217; BDBM32021; ACT03257; BCP28202; HY-N0105; NSC38629; ZINC4098704; Tox21_201098; ANW-30573; BBL009695; CR0016; LMPK13040015; NSC-38629; s2400; SBB001152; STL141046; AKOS005259272; AC-7978; ACN-035339; CS-5239; DB13174; MCULE-1248137705; NCGC00018199-01; NCGC00018199-02; NCGC00018199-03; NCGC00018199-04; NCGC00018199-05; NCGC00018199-06; NCGC00018199-07; NCGC00023342-03; NCGC00023342-04; NCGC00258650-01; AK-88490; AM807834; AS-11635; CAS-478-43-3; SY051290; AB0010467; DB-014981; D3986; FT-0645050; FT-0674401; N1810; 4, 5-Dihydroxyanthraquinone-2-carboxylic acid; 2-Anthraquinonecarboxylic acid, 4,5-dihydroxy-; 78R433; C10401; X-4365; Q720356; Q-100512; 4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; BRD-K27335680-001-01-9; 2-Anthroic acid,10-dihydro-4,5-dihydroxy-9,10-dioxo-; 4,5-dihydroxy-9,10-diketo-anthracene-2-carboxylic acid; 2-Anthracenecarboxylic acid,10-dihydro-4,5-dihydroxy-9,10-dioxo-; 2-Anthroic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo- (8CI); 4,5-bis(oxidanyl)-9,10-bis(oxidanylidene)anthracene-2-carboxylic acid; 4,5-Dihydroxy-9,10-dioxo-9,10-dihydro-2-anthracenecarboxylic acid #; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracene carboxylic acid; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid, 9CI
Click to Show/Hide
|
||||
| Species Origin | Rheum palmatum ... | Click to Show/Hide | |||
| Rheum palmatum | |||||
| Disease | Colitis [ICD-11: 1A40] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.187
MDCK Permeability
-4.738
PAMPA
+++
HIA
- -
Distribution
VDss
-0.784
PPB
97.8%
BBB
- - -
Metabolism
CYP1A2 inhibitor
+
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
- - -
Excretion
CLplasma
1.699
T1/2
1.543
Toxicity
DILI
+++
Rat Oral Acute Toxicity
+
FDAMDD
- -
Respiratory
++
Human Hepatotoxicity
++
Ototoxicity
+
Drug-induced Nephrotoxicity
++
Drug-induced Neurotoxicity
- -
Hematotoxicity
++
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C15H8O6
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)C(=O)O
|
||||
| InChI |
1S/C15H8O6/c16-9-3-1-2-7-11(9)14(19)12-8(13(7)18)4-6(15(20)21)5-10(12)17/h1-5,16-17H,(H,20,21)
|
||||
| InChIKey |
FCDLCPWAQCPTKC-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS CAS 478-43-3
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Calphostin c | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| RKO | CVCL_0504 | Colon carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Heat shock protein 90 alpha (HSP90A) | Molecule Info | [3] | |
| KEGG Pathway | Protein processing in endoplasmic reticulum | Click to Show/Hide | ||
| 2 | PI3K-Akt signaling pathway | |||
| 3 | Antigen processing and presentation | |||
| 4 | NOD-like receptor signaling pathway | |||
| 5 | Progesterone-mediated oocyte maturation | |||
| 6 | Estrogen signaling pathway | |||
| 7 | Pathways in cancer | |||
| 8 | Prostate cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
| 2 | TCR Signaling Pathway | |||
| Pathway Interaction Database | Signaling events mediated by HDAC Class II | Click to Show/Hide | ||
| 2 | Validated targets of C-MYC transcriptional activation | |||
| 3 | Integrin-linked kinase signaling | |||
| 4 | LKB1 signaling events | |||
| 5 | Regulation of Telomerase | |||
| 6 | Glucocorticoid receptor regulatory network | |||
| 7 | Class I PI3K signaling events | |||
| 8 | IL2 signaling events mediated by PI3K | |||
| 9 | Regulation of Androgen receptor activity | |||
| 10 | Integrins in angiogenesis | |||
| 11 | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | |||
| 12 | ErbB receptor signaling network | |||
| 13 | VEGFR1 specific signals | |||
| 14 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
| 15 | Class I PI3K signaling events mediated by Akt | |||
| Reactome | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | Click to Show/Hide | ||
| 2 | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||
| 3 | Regulation of actin dynamics for phagocytic cup formation | |||
| 4 | eNOS activation | |||
| 5 | Regulation of PLK1 Activity at G2/M Transition | |||
| 6 | Attenuation phase | |||
| 7 | HSF1-dependent transactivation | |||
| 8 | Loss of Nlp from mitotic centrosomes | |||
| 9 | Recruitment of mitotic centrosome proteins and complexes | |||
| 10 | Loss of proteins required for interphase microtubule organization?from the centrosome | |||
| 11 | EPHA-mediated growth cone collapse | |||
| 12 | VEGFA-VEGFR2 Pathway | |||
| 13 | VEGFR2 mediated vascular permeability | |||
| 14 | Anchoring of the basal body to the plasma membrane | |||
| 15 | Constitutive Signaling by EGFRvIII | |||
| WikiPathways | NRF2 pathway | Click to Show/Hide | ||
| 2 | Nuclear Receptors Meta-Pathway | |||
| 3 | Aryl Hydrocarbon Receptor Pathway | |||
| 4 | Binding and Uptake of Ligands by Scavenger Receptors | |||
| 5 | Signaling by ERBB2 | |||
| 6 | Fcgamma receptor (FCGR) dependent phagocytosis | |||
| 7 | Influenza Life Cycle | |||
| 8 | EBV LMP1 signaling | |||
| 9 | Aryl Hydrocarbon Receptor | |||
| 10 | Corticotropin-releasing hormone | |||
| 11 | TNF alpha Signaling Pathway | |||
| 12 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
| 13 | Signaling by EGFR | |||
| 14 | Semaphorin interactions | |||
| 15 | Mitotic G2-G2/M phases | |||
| 16 | Metabolism of nitric oxide | |||
| 17 | NOD pathway | |||